Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05335707
Other study ID # IIT-2021-GerioncBladder
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date September 14, 2022
Est. completion date August 21, 2023

Study information

Verified date February 2024
Source University of Kansas Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This single arm pilot study will evaluate the feasibility and acceptability for perioperative Comprehensive Geriatric Assessment (CGA) and CGA-directed supportive and restorative care for patients with muscle-invasive bladder cancer who are planned to undergo preoperative chemotherapy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 21, 2023
Est. primary completion date August 11, 2023
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent - Males and females age = 65 years - Diagnosis/disease status - Histologically proven muscle-invasive bladder cancer (MIBC) without metastatic disease. - Patients planning to undergo neoadjuvant chemotherapy and radical cystectomy for MIBC. - Treatment with investigational systemic therapy is permitted if participants will be receiving chemotherapy as part of their treatment plan Exclusion Criteria: - Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements - Any other known invasive malignancy within previous 2 years with the following EXCEPT: low grade prostate cancer on active surveillance, chronic lymphocytic leukemia CLL on surveillance / observation, non-melanoma skin cancers

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Kansas Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Develop a geriatric oncology assessment clinic and workflows Develop a geriatric oncology assessment clinic and workflows for the University of Kansas Health System, including University of Kansas Cancer Center St. Francis and Great Bend practices. 12 months
Secondary Test feasibility, acceptability, and preliminary impact Test feasibility, acceptability, and preliminary impact of the Comprehensive Geriatric Assessment (CGA) and CGA-directed care.
Note: The results of the CGA will be used by clinicians to guide patients' medical care.
12 months
See also
  Status Clinical Trial Phase
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Completed NCT03998579 - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer N/A
Not yet recruiting NCT04525781 - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Recruiting NCT05822934 - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Phase 3
Completed NCT06156787 - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed NCT02722538 - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Phase 1
Completed NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 1
Completed NCT02139371 - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 0
Completed NCT03433924 - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Completed NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Phase 2
Recruiting NCT05621837 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting NCT05644041 - Intravesical Gemcitabine in Patients With NMIBC Phase 2
Completed NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute N/A
Recruiting NCT04861584 - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Phase 2
Completed NCT01836978 - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy N/A
Terminated NCT01374789 - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer Phase 2
Recruiting NCT03844256 - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/Phase 2